可食用聚乙烯糖醇改性奇托纳米颗粒:从多相系统中分离和控制释放茶叶聚醇
Wenzhi Lei1, Jiangling Song1, Yanting Chen1
1College of Food Science and Engineering, Northwest A&F University, 712100 Yangling, Shaanxi, China.
International journal of biological macromolecules
|May 24, 2025
概括
这项研究引入了聚乙烯糖醇修饰的奇托纳米颗粒 (PEG-CS NPs),用于增强茶叶聚的输送. 这些纳米颗粒提高了多的稳定性,吸附性和生物可用性,以便在功能性食品和药物输送中潜在使用.
科学领域:
- 材料科学 材料科学 材料科学
- 生物技术是生物技术.
- 食品科学 食品科学 食品科学
背景情况:
- 茶叶中的多具有显著的抗氧化剂和脂质调节功效.
- 然而,它们的治疗潜力受到生物可用性和不稳定性差的限制.
研究的目的:
- 开发一种新型的聚乙烯糖醇 (PEG) 修饰的奇托桑纳米粒子 (CS NP) 系统,用于吸附和稳定茶叶多.
- 评估这些纳米颗粒的吸附能力,释放动力学和抗氧化活性.
主要方法:
- 合成了PEG-CSNP并对茶叶聚醇吸附进行了表征.
- 使用Elovich和Langmuir模型分析了吸附动力学和同热量.
- 评估了抗氧化剂活性和体外胃肠道释放概况.
主要成果:
- 优化的PEG-CSNP (0.3%PEG) 显示出高吸附能力,达到81.01 mg/g.
- 吸附遵循埃洛维奇动力学和兰格穆尔等温法,表明化学吸附.
- 在模拟的胃肠道条件下,PEG-CS NPs表现出持续的抗氧化活性和受控的多释放.
结论:
- 经PEG修饰的奇托桑纳米颗粒有效丰富,稳定和保护茶叶中的多.
- 这些纳米颗粒显示出作为功能性食品和药物输送系统中增强生物可用性的载体的承诺.
- 简化加工和减少聚醇损失比传统方法具有显著的优势.
相关概念视频
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
332
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
332
Modified-Release Drug Delivery Systems: Classification
315
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
315
Modified-Release Drug Delivery Systems: Rate-Programmed I
172
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
172
Modified-Release Drug Delivery Systems: Site-Targeted
164
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
164
Site-Targeted Drug Delivery Systems: Polymeric Carriers
160
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
160
Oral Drug Delivery Systems: Delayed-Release Systems
222
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
222


